Normal view

Received — 4 April 2026 ⏭ Journals

Cell
Genetically encoded fluorescent reporters to visualize α-synuclein pathology in live brain Li Zhang · Minhui Yu · Guoqing Chen · Siyuan Ge · Mengdi Wang · Xianying Zhang · Miao Zhao · Huating Gu · Meizhu Huang · Aixue Liu · Gengxin Ran · Zeyuan Liu · Tiepeng Liao · Qi Chen · Chenjian Miao · Yao Lu · Yibing Wang · Fengchao Wang · Zhihui Liu · Hongying Zhu · Qian Wu · Zhuan Zhou · Wei Xiong · Xiaoqun Wang · Peng Cao
The development of genetically encoded fluorescent reporters, along with their corresponding knock-in mouse lines for labeling α-Syn inclusions, enables diverse applications in studying the propagation and pathological effects of α-Syn inclusions in the live brain.
4 March 2026 at 08:00

Genetically encoded fluorescent reporters to visualize α-synuclein pathology in live brain

Cell

By: Li Zhang · Minhui Yu · Guoqing Chen · Siyuan Ge · Mengdi Wang · Xianying Zhang · Miao Zhao · Huating Gu · Meizhu Huang · Aixue Liu · Gengxin Ran · Zeyuan Liu · Tiepeng Liao · Qi Chen · Chenjian Miao · Yao Lu · Yibing Wang · Fengchao Wang · Zhihui Liu · Hongying Zhu · Qian Wu · Zhuan Zhou · Wei Xiong · Xiaoqun Wang · Peng Cao

4 March 2026 at 08:00

The development of genetically encoded fluorescent reporters, along with their corresponding knock-in mouse lines for labeling α-Syn inclusions, enables diverse applications in studying the propagation and pathological effects of α-Syn inclusions in the live brain.

Received — 26 March 2026 ⏭ Journals

Nature Medicine
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li
Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.
25 March 2026 at 08:00

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

Nature Medicine

By: Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li

25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6

In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.